Screener / SEC EDGAR /CIK 0001504776 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Eye Care

Warby Parker Inc. WRBY

Compare with peers Embed
Planned sales, announced before they happen

4 trading plans running, 33 Form 144 notices for $59.2M

10-Q, 10-K and Form 144

What WRBY's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Sep 13, 2024 to Jun 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Dave Gilboa
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Aug 19, 2026 10-Q Nov 5, 2026
What the company wrote
On August 19, 2026, Dave Gilboa, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 2,064,191 shares of our Class A common stock. The trading arrangement will expire on June 30, 2027 or earlier if all transactions under the trading arrangement are completed.
Neil Blumenthal
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Aug 18, 2026 10-Q Nov 5, 2026
What the company wrote
On August 18, 2026, Neil Blumenthal, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 750,000 shares of our Class A common stock. The trading arrangement will expire on June 30, 2027 or earlier if all transactions under the trading arrangement are completed.
Dave Gilboa
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Mar 17, 2026 10-Q May 7, 2026
What the company wrote
On March 17, 2026, Dave Gilboa, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,945,492 shares of our Class A common stock. The trading arrangement will expire on December 31, 2026 or earlier if all transactions under the trading arrangement are completed.
Neil Blumenthal
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Mar 17, 2026 10-Q May 7, 2026
What the company wrote
On March 17, 2026, Neil Blumenthal, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,500,000 shares of our Class A common stock. The trading arrangement will expire on December 31, 2026 or earlier if all transactions under the trading arrangement are completed.
Teresa Briggs
director
Adopted 10b5-1 plan Mar 17, 2026 10-Q May 7, 2026
What the company wrote
On March 17, 2026, Teresa Briggs, a director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 5,000 shares of our Class A common stock. The trading arrangement will expire on June 20, 2026 or earlier if all transactions under the trading arrangement are completed.
Dave Gilboa
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Sep 16, 2025 10-Q Nov 6, 2025
What the company wrote
On September 16, 2025, Dave Gilboa, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,000,000 shares of our Class A common stock. The trading arrangement will expire on June 30, 2026 or earlier if all transactions under the trading arrangement are completed.
Neil Blumenthal
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Sep 16, 2025 10-Q Nov 6, 2025
What the company wrote
On September 16, 2025, Neil Blumenthal, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,600,000 shares of our Class A common stock. The trading arrangement will expire on June 30, 2026 or earlier if all transactions under the trading arrangement are completed.
Dave Gilboa
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Mar 14, 2025 10-Q May 8, 2025
What the company wrote
On March 14, 2025, Dave Gilboa, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,050,000 shares of our Class A common stock. The trading arrangement will expire on December 31, 2025 or earlier if all transactions under the trading arrangement are completed.
Neil Blumenthal
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Mar 14, 2025 10-Q May 8, 2025
What the company wrote
On March 14, 2025, Neil Blumenthal, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,100,000 shares of our Class A common stock. The trading arrangement will expire on December 31, 2025 or earlier if all transactions under the trading arrangement are completed.
Dave Gilboa
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Sep 13, 2024 10-Q Nov 7, 2024
What the company wrote
On September 13, 2024, Dave Gilboa, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 950,000 shares of our Class A common stock. The trading arrangement will expire on June 30, 2025 or earlier if all transactions under the trading arrangement are completed.
Neil Blumenthal
Co-Chief Executive Officer and director
Adopted 10b5-1 plan Sep 13, 2024 10-Q Nov 7, 2024
What the company wrote
On September 13, 2024, Neil Blumenthal, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,250,000 shares of our Class A common stock. The trading arrangement will expire on June 30, 2025 or earlier if all transactions under the trading arrangement are completed.
Teresa Briggs
member of our board of directors
Adopted 10b5-1 plan Mar 14, 2024 10-Q May 9, 2024
What the company wrote
On March 14, 2024, Teresa Briggs, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c). The trading arrangement provides for the sale of 50% of the number of shares of our Class A common stock to be received as fully vested RSUs following our 2024 annual meeting of stockholders pursuant to our Director Compensation Program. The aggregate number of shares sold under the trading arrangement will depend on the average closing trading price of our Class A common stock over the 30-day period ending the day prior to the date of such annual meeting. The trading arrangement will expire on December 31, 2024 or earlier if all transactions under the trading arrangement are completed.
Dave Gilboa
Co-Chief Executive Officer and director
Adopted plan Nov 22, 2023 10-K Feb 29, 2024
What the company wrote
On November 22, 2023, Dave Gilboa, our Co-Chief Executive Officer and director, modified a Rule 10b5-1 trading arrangement originally adopted on September 14, 2023. The modified trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 1,209,080 shares of our Class A common stock. The modified trading arrangement will expire on December 31, 2024 or earlier if all transactions under the trading arrangement are completed.
Dave Gilboa
Co-Chief Executive Officer and director
Adopted other arrangement Sep 14, 2023 10-Q Nov 8, 2023
What the company wrote
On September 14, 2023, Dave Gilboa, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 1,209,080 shares of our Class A common stock. The trading arrangement will expire on December 31, 2024 or earlier if all transactions under the trading arrangement are completed.
Neil Blumenthal
Co-Chief Executive Officer and director
Adopted other arrangement Sep 14, 2023 10-Q Nov 8, 2023
What the company wrote
On September 14, 2023, Neil Blumenthal, our Co-Chief Executive Officer and director, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 950,000 shares of our Class A common stock. The trading arrangement will expire on December 31, 2024 or earlier if all transactions under the trading arrangement are completed.
Steve Miller
Chief Financial Officer,
Adopted other arrangement Aug 29, 2023 10-Q Nov 8, 2023
What the company wrote
On August 29, 2023, Steve Miller, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) providing for the sale of up to an aggregate of 112,461 shares of our Class A common stock. The aggregate number of shares sold under the plan may differ based on tax withholdings for vesting stock awards. The trading arrangement will expire on December 31, 2024 or earlier if all transactions under the trading arrangement are completed.
Show the other 8 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 9, 2026 DAVID GILBOA
Director, Officer
75,402 $1.9M
Nov 9, 2026 NEIL BLUMENTHAL
Director, Officer
73,133 $1.9M
Nov 9, 2026 JEFFREY RAIDER
Director
30,000 $764K
Oct 1, 2026 JEFFREY RAIDER
Director
15,000 $417K
Oct 1, 2026 NEIL BLUMENTHAL
Director, Officer
100,000 $2.8M
Jul 6, 2026 NEIL BLUMENTHAL
Director, Officer
9,200 $269K
Jul 6, 2026 DAVID GILBOA
Director, Officer
54,347 $1.6M
Jul 1, 2026 NEIL BLUMENTHAL
Director, Officer
217,667 $6.6M
Jul 1, 2026 DAVID GILBOA
Director, Officer
242,221 $7.3M
Jul 1, 2026 JEFFREY RAIDER
Director
22,500 $683K
Jun 29, 2026 NEIL BLUMENTHAL
Director, Officer
36,300 $1.1M
Jun 16, 2026 TERESA BRIGGS
Director
5,000 $132K
Jun 12, 2026 YOUNGME MOON
Director
10,000 $265K
May 19, 2026 NEIL BLUMENTHAL
Director, Officer
63,040 $1.8M
May 13, 2026 Bradley Singer
Director
25,000 $674K
Apr 17, 2026 NEIL BLUMENTHAL
Director, Officer
50,000 $1.2M
Apr 16, 2026 NEIL BLUMENTHAL
Director, Officer
50,000 $1.2M
Mar 11, 2026 JEFFREY RAIDER
Director
25,000 $636K
Mar 4, 2026 BRADLEY SINGER
Director
15,793 $435K
Jan 13, 2026 DAVID GILBOA
Director, Officer
80,094 $2.1M
Jan 13, 2026 NEIL BLUMENTHAL
Director, Officer
660 $18K
Jan 9, 2026 DAVID GILBOA
Director, Officer
19,906 $563K
Jan 7, 2026 NEIL BLUMENTHAL
Director, Officer
50,000 $1.3M
Jan 7, 2026 DAVID GILBOA
Director, Officer
75,000 $1.9M
Jan 6, 2026 NEIL BLUMENTHAL
Director, Officer
150,000 $3.5M
Jan 6, 2026 DAVID GILBOA
Director, Officer
50,000 $1.2M
Jan 2, 2026 DAVID GILBOA
Director, Officer
25,000 $545K
Dec 16, 2025 Joel Cutler
Director
32,249 $859K
Dec 15, 2025 Warby Parker Impact Foundation
10% Stockholder
178,572 $4.9M
Dec 12, 2025 JEFFREY RAIDER
Officer
25,000 $686K
Dec 11, 2025 David Gilboa
Director, Officer
200,000 $5.9M
Dec 11, 2025 NEIL BLUMENTHAL
Director, Officer
100,000 $3.0M
Dec 11, 2025 YOUNGME MOON
Director
38,832 $1.1M
Show the other 25 notices

From the Form 144 XML filed with the SEC, since Dec 11, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WRBY/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.